Taiho Oncology has announced plans to present crucial real-world clinical data at the upcoming 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco, offering new insights into metastatic colorectal cancer (mCRC) treatment outcomes.
The presentations, scheduled for January 25, 2025, will feature two distinct analyses examining the effectiveness of trifluridine and tipiracil (FTD/TPI) treatments in different patient populations. The research specifically compares outcomes between FTD/TPI monotherapy and its combination with bevacizumab (FTD/TPI+bev).
Real-World Outcomes Analysis
The first study, to be presented by Dr. Maliha Nusrat, will provide comprehensive data comparing clinical outcomes in mCRC patients receiving either FTD/TPI alone or in combination with bevacizumab. This analysis aims to inform clinical development strategies and optimize treatment protocols for the broader patient population.
Focus on Diversity in Clinical Outcomes
Of particular significance is the second analysis, which specifically examines treatment outcomes in 639 Black patients with mCRC. This focused study represents an important step toward understanding treatment efficacy in historically underrepresented populations.
"Access to real-world clinical outcomes of FTD/TPI monotherapy versus FTD/TPI+bev combination therapy among patients with mCRC could provide valuable insights to ultimately help improve clinical development and treatment protocols, broadly and in underrepresented populations," said Dr. Tehseen Salimi, Senior Vice President and Head of Medical Affairs at Taiho Oncology.
Clinical Impact and Future Implications
These analyses are expected to contribute significantly to the understanding of treatment effectiveness in real-world settings, potentially influencing future treatment decisions and protocol development. The inclusion of a large cohort of Black patients particularly addresses the growing emphasis on diversity in clinical research and treatment optimization.
Both poster presentations will be available at Level 1, West Hall, and will also be accessible on-demand during the symposium. The research represents Taiho Oncology's commitment to advancing cancer treatment through real-world evidence and inclusive research practices.
